GTHP — Guided Therapeutics Balance Sheet
0.000.00%
- $8.19m
- $9.80m
- $0.01m
Annual balance sheet for Guided Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.182 | 0.643 | 2.31 | 0.591 | 0.388 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.024 | 0.046 | 0.006 | 0.007 | 0.003 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.896 | 1.64 | 3 | 1.39 | 1.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.454 | 0.386 | 0.345 | 0.259 | 0.164 |
Other Long Term Assets | |||||
Total Assets | 1.35 | 2.04 | 3.37 | 1.67 | 1.38 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.96 | 5.69 | 4.87 | 4.81 | 6.16 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 12.2 | 7.49 | 6.25 | 5.47 | 6.27 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Total Equity | -10.9 | -5.45 | -2.88 | -3.81 | -4.89 |
Total Liabilities & Shareholders' Equity | 1.35 | 2.04 | 3.37 | 1.67 | 1.38 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |